Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes - PubMed (original) (raw)

. 2018 Aug;41(8):e129-e130.

doi: 10.2337/dc18-0394. Epub 2018 Jun 25.

Affiliations

• PMID: 29941496
• PMCID: PMC6054503
• DOI: 10.2337/dc18-0394

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

Petter Bjornstad et al. Diabetes Care. 2018 Aug.

No abstract available

PubMed Disclaimer

Figures

Figure 1

Changes from baseline in FeNA+ and eGFR after single-dose administration of empagliflozin (n = 27), adjusted for baseline value, age, sex, HbA1c, and BMI standard deviation score. Directions of effect on FeNA+ and eGFR were consistent across the three doses of empagliflozin tested.

Similar articles

• The kidney and cardiovascular outcome trials.
  Bloomgarden Z. Bloomgarden Z. J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616. J Diabetes. 2018. PMID: 29031006
• Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
  Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13. Circulation. 2018. PMID: 28904068 Clinical Trial.
• Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
  Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V. Fu Y, et al. Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F386-F394. doi: 10.1152/ajprenal.00503.2017. Epub 2018 Feb 7. Am J Physiol Renal Physiol. 2018. PMID: 29412698 Free PMC article.
• Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
  Dailey G. Dailey G. J Diabetes. 2015 Jul;7(4):448-61. doi: 10.1111/1753-0407.12278. Epub 2015 May 18. J Diabetes. 2015. PMID: 25676662 Review.
• Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
  Dixit D, Yoon Y, Volino LR, Mansukhani RP. Dixit D, et al. Am J Health Syst Pharm. 2015 Nov 15;72(22):1943-54. doi: 10.2146/ajhp150071. Am J Health Syst Pharm. 2015. PMID: 26541949 Review.

Cited by

• Youth-onset Type 2 Diabetes: An Overview of Pathophysiology, Prognosis, Prevention and Management.
  Titmuss A, Korula S, Wicklow B, Nadeau KJ. Titmuss A, et al. Curr Diab Rep. 2024 Aug;24(8):183-195. doi: 10.1007/s11892-024-01546-2. Epub 2024 Jul 3. Curr Diab Rep. 2024. PMID: 38958831 Free PMC article. Review.
• Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
  Tommerdahl KL, Kula AJ, Bjornstad P. Tommerdahl KL, et al. Expert Opin Pharmacother. 2023 Jun;24(8):913-924. doi: 10.1080/14656566.2023.2203319. Epub 2023 Apr 18. Expert Opin Pharmacother. 2023. PMID: 37071054 Free PMC article. Review.
• Youth-onset type 2 diabetes mellitus: an urgent challenge.
  Bjornstad P, Chao LC, Cree-Green M, Dart AB, King M, Looker HC, Magliano DJ, Nadeau KJ, Pinhas-Hamiel O, Shah AS, van Raalte DH, Pavkov ME, Nelson RG. Bjornstad P, et al. Nat Rev Nephrol. 2023 Mar;19(3):168-184. doi: 10.1038/s41581-022-00645-1. Epub 2022 Oct 31. Nat Rev Nephrol. 2023. PMID: 36316388 Free PMC article. Review.
• Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
  Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Frederich R, Maldonado M, Liu CC, Pong A, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Am J Nephrol. 2022;53(7):516-525. doi: 10.1159/000524889. Epub 2022 Jun 10. Am J Nephrol. 2022. PMID: 35691283 Free PMC article. Clinical Trial.

References

1. 1. Bjornstad P, Nehus E, El Ghormli L, et al. .; TODAY Study Group . Insulin sensitivity and diabetic kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. Am J Kidney Dis 2018;71:65–74 - PMC - PubMed
2. 1. Zinman B, Wanner C, Lachin JM, et al. .; EMPA-REG OUTCOME Investigators . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128 - PubMed
3. 1. Wanner C, Inzucchi SE, Lachin JM, et al. .; EMPA-REG OUTCOME Investigators . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–334 - PubMed
4. 1. Cherney DZ, Perkins BA, Soleymanlou N, et al. . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587–597 - PubMed
5. 1. Fadrowski JJ, Neu AM, Schwartz GJ, Furth SL. Pediatric GFR estimating equations applied to adolescents in the general population. Clin J Am Soc Nephrol 2011;6:1427–1435 - PMC - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal